Targeted therapy in renal cell carcinoma

Current Opinion in Urology

Volumn 18, Issue 5, 2008, Pages 481-487

  Vakkalanka, Bhanu K ^a   Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Mammalian target of rapamycin; Multikinase inhibitors; Renal cell carcinoma; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AXITINIB; BEVACIZUMAB; CEDIRANIB; ERLOTINIB; EVEROLIMUS; INTERFERON; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VOLOCIXIMAB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAIR DISCOLORATION; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INTESTINE PERFORATION; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE; VOICE CHANGE; VOMITING; DRUG POTENTIATION; IMMUNOLOGY; KIDNEY TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 54549116867     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32830a70cf     Document Type: Review

References (35)

1. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (Suppl 1):S55-S57.
2. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:33-141.
3. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18:2972-2980.
4. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338:1272-1278.
5. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-3132.
6. Clifford SC, Prowse AH, Affara NA, et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998; 22:200-209.
7. Krieg M, Haas R, Brauch H, et al. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cellsby von Hippel-Lindau tumor suppressor gene loss offunction. Oncogene 2000; 19:5435-5443.
8. Igarashi H, Esumi M, Ishida H, et al. Vascular endothelial growth factor over expression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 2002; 95:47-53.
9. Sulzbacher I, Birner P, Traxler M, et al. Expression of platelet-derived growth factor-aa receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 2003; 120:107-112.
10. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008; 14:1286-1290.
11. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-2512.
12. Escudier B, Eisen T, Stadler WM, et al., TARGET Study group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
13. Bukowski R, Cella D, Gondek R, et al. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007; 30:220-227.
14. Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of the multikinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006, ASCO Annual Meeting Proceedings; 24 (Suppl 18):4501.
15. Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25:3296-3301.
16. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25:3288-3295.
17. Bracarda S, Porta C, Boni C, et al. and GOIRC Study group. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681 [abstract 357]. In: Genito urinary cancers symposium proceedings; 14-16 February 2008; San Francisco: American Society of Clinical Oncology; 2008.
18. Rini BI, Hutson TE, Elson P, et al. A prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract 346]. In: Genito urinary cancers symposium proceedings; 14-16 February 2008; San Francisco: American Society of Clinical Oncology; 2008.
19. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337.
20. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
21. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
22. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
23. Chouieri T, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-131.
24. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
25. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25:4536-4541.
26. Escudier B, Pluzanska A, Koralewski P, et al., AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103-2111.
27. Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma [abstract 350]. In: Genitourinary cancers symposium; 14-16 February 2008; San Francisco: American Society of Clinical Oncology; 2008.
28. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918.
29. Hudes G, Carducci M, Tomczak P, et al., Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 2007; 356:2271-2281.
30. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer: a phase II study. Lancet Oncol 2007; 8:975-984.
31. Rini BI, Wilding GT, Hudes G, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 2007, ASCO Annual Meeting Proceedings; 25 (Suppl 18):5032.
32. Sridhar S, Hotte SJ, Mackenzie MJ, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): a trial of the PMH Phase II Consortium. J Clin Oncol 2007, ASCO Annual Meeting Proceedings; 25 (Suppl 18):5093.
33. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007, ASCO Annual Meeting Proceedings; 25 (Suppl 18):5031.
34. Yazi S, Bukowski R, Kondagunta V, et al. Final results from phase II study of volociximab, an α5β1 antiintegrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). J Clin Oncol 2007, ASCO Annual Meeting Proceedings; 25 (Suppl 18):5094.
35. Amato RJ, Misellati A, Khan M, et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2006, ASCO Annual Meeting Proceedings; 24 (Suppl 18):4530.